Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Metastatic × fludarabine × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 38 Breast Neoplasms 14 Uterine Cervical Neoplasms 13 Melanoma 13 Carcinoma, Non-Small-Cell Lung 13 Pancreatic Neoplasms 11 Colorectal Neoplasms 10 Neoplasm Metastasis 8 Stomach Neoplasms 7 Head and Neck Neoplasms 7 Triple Negative Breast Neoplasms 6 Fallopian Tube Neoplasms 6 Esophageal Neoplasms 6 Anus Neoplasms 6 Vaginal Neoplasms 5 Penile Neoplasms 5 Lung Neoplasms 5 Carcinoma, Hepatocellular 5 Vulvar Neoplasms 4 Urogenital Neoplasms 4 Urinary Bladder Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Oropharyngeal Neoplasms 4 Neoplasms 4 Multiple Myeloma 4 Mesothelioma 4 Carcinoma, Renal Cell 4 Carcinoma, Ovarian Epithelial 4 Sarcoma, Synovial 3 Recurrence 3

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡